The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Background IMspire150 aimed to evaluate first-line combination treatment with BRAF plus
MEK inhibitors and immune checkpoint therapy in BRAF V600 mutation-positive advanced …

Background PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line
treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there …

Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers.
Consistent basic data suggest that these same checkpoints are critical negative regulators of …

The immune cells within the tumor microenvironment (TME) play important roles in
tumorigenesis. It has been known that these tumor associated immune cells may possess …

The authors concluded by use of epidemiological statistics that because the proportion of
patients with cancer histories was higher in a cohort with COVID-19 than in the population in …

Background Numerous ongoing trials are testing anti-PD-1-based or anti-PD-L1-based
cancer treatment combinations. Understanding the toxicity profiles of treatment-related …

Importance Non–small cell lung cancer remains the leading cause of cancer death in the
United States. Until the last decade, the 5-year overall survival rate for patients with …